GPT and hypertriglyceridemia: According to the existing evidence, including our study, pemafibrate can undoubtedly ameliorate liver dysfunction assessed by LFTs (especially ALT, GGT, and ALP levels) in NAFLD patients with hypertriglyceridemia after only 12 weeks of administration.